| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
The Oncology Institute, Inc. Common Stock$5.03
+0.05 (+1%)
Market Cap
304.42 M
EPS
-0.56
P/E Ratio
-5.47 $
Value Trade
5.81 M
SEC Financials
Q1 2026Dilution Risk
Revenue
147.44 M
Operating CF
-2.21 M
Total Assets
168.23 M
Total Liabilities
184.51 M
Equity
-16.29 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
30.28 M
Monthly Burn
738.00 K
Runway
39.6 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.16 M
52 Week Range
1.80 - 4.88
% held by Insiders
36.4 %
% held by Institutions
35.56 %
Enterprise Value
374.61 M
Total Shares
98.43 M
Short %
7.87 %
Float Shares
81.60 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TOI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
The Oncology Institute, Inc. Common Stock (TOI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TOI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TOI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TOI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TOI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TOI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-TOI
May 7, 2026The Oncology Institute Reports First Quarter 2026 Financial Results
The Oncology Institute Reports First Quarter 2026 Financial Results Calif., May 7, 2026 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for i
Read more →-TOI
Mar 12, 2026The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026
The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 CERRITOS, Calif., March 12, 2026 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the Un
Read more →-TOI
Feb 23, 2026The Oncology Institute Appoints Kim Tzoumakas to Board of Directors
The Oncology Institute Appoints Kim Tzoumakas to Board of CERRITOS, Calif., Feb 23, 2026 (Global NEWSWIRE) - The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumaka
Read more →-TOI
Jan 12, 2026The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook
The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook CERRITOS, Calif., January 12, 2026 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based oncology groups in the United States,
Read more →-TOI
Jan 5, 2026The Oncology Institute Announces Addition of Board Member Mark Stolper
Oncology Institute Announces Addition of Board Member Mark Stolper CERRITOS, Calif., January 5, 2026 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper ha
Read more →-TOI
Dec 1, 2025The Oncology Institute Announces Resignation of Board Member Gabe Ling
The Oncology Institute Announces Resignation of Board Member CERRITOS, Calif., December 1, 2025 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resign
Read more →-TOI
Nov 14, 2025THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ( L y 2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ~ Some of the information in this presentation is not historical in nature and may constitute forward - looking statements,
1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ( L y < 2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ~ Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions
Read more →-TOI
Nov 13, 2025The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance Calif., November 13, 2025 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United St
Read more →-TOI
Aug 13, 2025The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance Calif., August 13, 2025 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United Sta
Read more →-TOI
Aug 13, 2025The Oncology Institute Announces Changes to Board of Directors Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman
The Oncology Institute Announces Changes to Board of Directors Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman CERRITOS, Calif., August 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI) one
Read more →-TOI
May 19, 2025THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION May 2025 This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the PIPE Financing) involving The Oncology Inst
1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION May 2025 This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the PIPE Financing) involving The Oncology Institute, Inc. (the "Company"), and for no other purpose. Th
Read more →-TOI
May 14, 2025The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance Calif., May 14, 2025 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States,
Read more →-TOI
Mar 24, 2025The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025 CERRITOS, Calif., March 24, 2025 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the Un
Read more →-TOI
Mar 24, 2025THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Q February 2025 2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION % This presentation is being furnished solely for the purpose of considering a potential private placement of secu
1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Q February 2025 2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION % This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the " PIP E Financing") involving The Oncology In
Read more →-TOI
Mar 24, 2025The Oncology Institute Announces $16.5 million Private Placement
The Oncology Institute Announces $16.5 million Private Placement CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today anno
Read more →-TOI
Feb 26, 2025The Oncology Institute Announces Amendment to Facility Agreement and Debt Paydown
The Oncology Institute Announces Amendment to Facility Agreement and Debt Paydown CERRITOS, Calif., February 26, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the Unite
Read more →-TOI
Sep 23, 2024The Oncology Institute Announces CFO Transition Rob Carter promoted to Chief Financial Officer
The Oncology Institute Announces CFO Transition Rob Carter promoted to Chief Financial Officer CERRITOS, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), today announced that Chief Financial Officer, Mihir Shah,
Read more →-TOI
Jun 12, 2023toitransitionpress 6/9/23, 1:42 PM the-oncology-institute-announces-leadership-transition https://prdesk.globenewswire.com/JobPreview/PnrArticlePreview?t=5640719&l=eng 1/2 The Oncology Institute Announces Leadership Tran
6/9/23, 1:42 PM the-oncology-institute-announces-leadership-transition https://prdesk.globenewswire.com/JobPreview/PnrArticlePreview?t=5640719&l=eng 1/2 The Oncology Institute Announces Leadership Transition Dr. Daniel Virnich promoted from President to CEO. Brad Hively will tran
Read more →-TOI
Aug 9, 2022Document The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets Investment to accelerate Company's expansion into new markets, bringing hig
The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets Investment to accelerate Company's expansion into new markets, bringing high-quality, value-based care to more patients CERRITOS, Calif., Augu
Read more →-TOI
Mar 11, 2022toiinvestorpr Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Re
Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Relationships with Leading Payors and Risk Taking Providers Our Growth (Rev
Read more →-TOI
Nov 18, 2021TOI Parent, Inc. Table of Contents Financial Statements 2 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations (Unaudited) 4 Condensed Consolidated Statements of Convertible
Financial Statements 2 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations (Unaudited) 4 Condensed Consolidated Statements of Convertible Preferred Shares and Changes in Stockholders' Deficit (Unaudited) 5 Condensed Consolidated Sta
Read more →-TOI
Nov 15, 2021GlobeNewswire COVID-19 NEWS SERVICESv CONTACT us FRAN ,;AIS SIGN IN by notified f w in ~ The Oncology Institute Completes Business Combination with DFP Healthcare Acquisitions Corp. to Become Publicly-Traded Company
Explore Finnish TamP-ere Deck Arena is now Nokia Arena .. : ., . - GlobeNewsw1 re by notified About Us ~ CNt INDUSTRIAL SUSTAINABILITY LEADER CNH Industrial maintains its tOP P-Osition in the ... GlobeNewswire is one of the world's largest newswire distribution networks, speciali
Read more →-TOI
Oct 22, 2021DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute Special Meeting of Stockholders Scheduled for
DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute Special Meeting of Stockholders Scheduled for NEW YORK, October 22, 2021 -- DFP Healthcare Acquisitions Corp. ("DFP") (Nasdaq: DFPH) announc
Read more →-TOI
Oct 12, 2021The Leader in Value Based Oncology Care October 2021 Analyst Day Presentation Disclaimer and Forward Looking Statements 2 Disclaimer: This presentation is provided for informational purposes only and has been prepared to
The Leader in Value Based Oncology Care October 2021 Analyst Day Presentation Disclaimer and Forward Looking Statements 2 Disclaimer: This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation w
Read more →-TOI
Jun 28, 2021DFP Healthcare Acquisitions Corp. ANNOUNCES PROPOSED BUSINESS COMBINATION WITH the oncology institute The Oncology Institute is the U.S. Market Leader in Value-Based Oncology Care New York, NY and L
Healthcare Acquisitions Corp. ANNOUNCES PROPOSED BUSINESS COMBINATION WITH the oncology institute The Oncology Institute is the U.S. Market Leader in Value-Based Oncology Care New York, NY and Los Angeles, CA - June 28, 2021 - DFP Healthcare Acquisitions Corp ("DFP") (NASDAQ:
Read more →-TOI
May 1, 2020DFP Healthcare Acquisitions Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about
Healthcare Acquisitions Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about May 1, 2020 YORK, April 28, 2020 - DFP Healthcare Acquisitions Corp. (the "Company") announced today that holders of the units sold in the Company's in
Read more →-TOI
Mar 13, 2020DFP HEALTHCARE ACQUISITIONS CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 Report of Independent Registered Public Accounting Firm To the Stockholders and t
HEALTHCARE ACQUISITIONS CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 of Independent Registered Public Accounting Firm and the Board of Directors of on the Financial Statement the accompanying balance sheet of
Read more →-TOI
Mar 10, 2020DFP Healthcare Acquisitions Corp. Announces Pricing of $200 Million Initial Public Offering
Acquisitions Corp. Announces Pricing of $200 Million Initial Public Offering 10, 2020 - DFP Healthcare Acquisitions Corp. (the "Company") announced today the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units will be listed on Th
Read more →Competitive Position
How TOI ranks across every disease it competes inCompetitive Position is a premium feature
See how TOI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial